Isto Technologies acquired Arteriocyte Medical Systems, forming Isto Biologics. The new entity will offer evidence-based solutions for spine and orthopaedic applications. Terms were not disclosed.
The combined product portfolio will focus on biologics and cell therapies, featuring the MAGELLAN® Autologous Platelet Separator, InQu® Bone Graft Extender & Substitute, Influx® bone graft material and the CellPoint® bone marrow aspirate system.
Isto received an initial FDA 510(k) clearance for InQu in 2007, with CE Mark Approval following in 2011. The company was established in 1997 and purchased by private equity firm Thompson Street Capital in late 2Q16. As noted at that time, Thompson planned complementary acquisitions to support Isto’s product development, salesforce expansion and increase the company’s reach within spine and orthopaedics.
Arteriocyte was formed in 2007 to develop products to support healing, such as MAGELLAN, the MAR0Max™ Kit for aspiration, concentration and delivery of whole blood and bone marrow, and DBM Powder (MAR0Match™) and DBM Gel (MAR0Fuse™) derived from a single donor.
Sources: Isto Biologics; arteriocyte.com; ORTHOWORLD Inc.
Isto Technologies acquired Arteriocyte Medical Systems, forming Isto Biologics. The new entity will offer evidence-based solutions for spine and orthopaedic applications. Terms were not disclosed.
The combined product portfolio will focus on biologics and cell therapies, featuring the MAGELLAN® Autologous Platelet Separator, InQu® Bone...
Isto Technologies acquired Arteriocyte Medical Systems, forming Isto Biologics. The new entity will offer evidence-based solutions for spine and orthopaedic applications. Terms were not disclosed.
The combined product portfolio will focus on biologics and cell therapies, featuring the MAGELLAN® Autologous Platelet Separator, InQu® Bone Graft Extender & Substitute, Influx® bone graft material and the CellPoint® bone marrow aspirate system.
Isto received an initial FDA 510(k) clearance for InQu in 2007, with CE Mark Approval following in 2011. The company was established in 1997 and purchased by private equity firm Thompson Street Capital in late 2Q16. As noted at that time, Thompson planned complementary acquisitions to support Isto’s product development, salesforce expansion and increase the company’s reach within spine and orthopaedics.
Arteriocyte was formed in 2007 to develop products to support healing, such as MAGELLAN, the MAR0Max™ Kit for aspiration, concentration and delivery of whole blood and bone marrow, and DBM Powder (MAR0Match™) and DBM Gel (MAR0Fuse™) derived from a single donor.
Sources: Isto Biologics; arteriocyte.com; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
